All posts by Vishal Dalwadi

Quadrant Future Tek IPO – Review, Update


Update Secures New Business Order Quadrant Future-Tek Limited, which manufactures specialty cables and develops train control & signalling systems, in its regulatory filing has said that, The company has secured a new business order from Integral Coach Factory, Chennai (ICF) on January 28, 2026, for the Supply, Retrofitment, Testing, and Commissioning of 192 Onboard KAVACH Equipment Version 4.0, including warranty and Long-Term Annual Maintenance. The value of the contract is worth

Shadowfax IPO – Review, Update


Update: Shadowfax ipo listing Shadowfax Technologies Ltd, Bengaluru-based tech-led logistics solutions provider, made a weak debut on the stock market on January 28, 2026. The weak listing came despite the company’s ₹1,907 Cr IPO receiving a decent subscription of 2.72 times (according to stock exchange data) during January 20-22. The stock opened at ₹113 per share on the Bombay Stock Exchange (BSE) against the IPO price of ₹124, representing a discount of about 8.85%. On the National Stock

Antony Waste Handling Cell Ltd IPO – Review, Update


Update: Equity Stake Purchased by the US hedge fund Data from the NSE bulk deals report suggests that the US-based Miri Capital Management-owned Miri Strategic Emerging Markets Fund has acquired an additional 1.49% equity stake (more than 4 lakh shares) in Antony Waste Handling Cell Limited, a leading player in the Indian Municipal Solid Waste Management industry, via open market transactions on January 23, 2026. Shares of Antony Waste Handling Cell jumped nearly 13.8% to close at a high of

Urban Company IPO – Review, Update


Update: Q3 FY26 Numbers Urban Company Ltd, India’s leading home services platform, has announced its financial results for the quarter ended December 31, 2025 (Q3 FY26) later today. The company delivered broad-based growth for the quarter ended December 31, 2025, with Net Transaction Value (NTV) up 36 percent Year-over-Year (YoY) (excluding KSA) to ₹1,081 Cr and revenue from operations up 42 percent YoY to ₹383 Cr. India Consumer Services (Ex InstaHelp) grew 21 percent Y-o-Y in Net

HDB Financial Services IPO – Review, Update


Update: Resignation of Independent Director HDB Financial Services Ltd (HDFC Bank's subsidiary) on January 23, 2026, said that Mr. Arijit Basu (DIN: 06907779) has tendered his resignation as the Non-Executive Independent Director & Chairman of the Company with immediate effect, for reasons as mentioned in the resignation letter.     Refer to Hdb financial services latest news today for more details. In the second half of the day, private lender IndusInd Bank Ltd said

Amagi Media Labs IPO – Review, Update


Update: Amagi Media Labs "Listing" Amagi Media Labs Ltd, a "SaaS" based company, made a weak debut on the bourse on January 21, 2026. The stock opened at ₹317 per share on the Bombay Stock Exchange (BSE) against the IPO price of ₹361, representing a discount of about 12%. On the National Stock Exchange (NSE), the stock opened at ₹318 per share, reflecting a discount. The Stock made a high of ₹356.95 and a low of ₹318 before it ended at ₹348.25 (down 3.50%) on the NSE when the market

Schloss Bangalore IPO – Review, Update


Update: Q3 FY26 Numbers Leela Palaces Hotels & Resorts Limited announced its financial and operational results for the quarter ending December 31, 2025 (Q3 FY26) on January 16, 2026. The company's operating revenue grew 21 percent year-over-year (Y-o-Y) to ₹457.4 Cr, while operating EBITDA increased 23 percent to ₹237.8 Cr for the same period. Profit after tax ( PAT) surged 162 percent to ₹147.9 Cr, marking the best quarterly performance. The Company delivered its fifth consecutive

Metropolis Healthcare Limited IPO: Review, Update


Update: Launches Centre of Genomics Metropolis Healthcare Limited, India’s second-largest pathology laboratory chain, today announced the launch of its Centre of Genomics, marking a significant step in scaling its longstanding capabilities in advanced genomics, precision medicine, molecular diagnostics, and genomic research. The Centre of Genomics is designed to deliver clinically actionable genomic insights across the care continuum, supporting multiple high-impact clinical

1 2 3 46